N-terminal pro-B-type natriuretic peptide in atrial fibrillation: time to look beyond clinical risk scores, or not?

Biomarker-Based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry-Based, Multicenter, Randomized, Controlled Study

10.1161/circulationaha.125.076725 · doi-reference

Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation

10.1161/circulationaha.120.053100 · doi-reference

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation

10.1016/j.jacc.2024.11.052 · doi-reference

Biomarkers of Cardiac Dysfunction and Mortality from Community-Acquired Pneumonia in Adults

10.1371/journal.pone.0062612 · doi-reference

10.1016/j.ejim.2007.01.006

10.1016/j.ejim.2007.01.006 · doi-reference

Dynamic biomarker profiles in patients with paroxysmal atrial fibrillation: Assessing the differences between sinus rhythm and acute atrial fibrillation episode

10.1016/j.ijcard.2024.132526 · doi-reference

10.1136/heartjnl-2026-328033

10.1136/heartjnl-2026-328033 · doi-reference

10.1093/eurheartj/ehae176

10.1093/eurheartj/ehae176 · doi-reference